Clinical and Pathological Characteristics and Outcomes of Clear Cell Carcinoma of Ovary: A Tertiary Cancer Centre Data
- 1 Downloads
Clear cell carcinoma of ovary is a rare disease. Historically, they have been treated in lines of serous ovarian cancer. But available evidence shows different outcomes in these cancers. There is a paucity of data on the outcomes of clear cell carcinoma from India. Here were present the outcomes from a tertiary cancer centre.
This was a retrospective study. All patients diagnosed with clear cell carcinoma of the ovary in our centre between 2011 and 2017 were analysed. Only those who had pathological confirmation in our hospital were included. Their clinical and pathological characteristics and outcomes were analysed and compared between subsets using Kaplan–Meier method and log-rank test.
A total of 46 patients were included in the analysis. Median age was 51.6 years (range 29–69 years). The mean baseline CA-125 was 541.52 U/ml (range 6–6137 U/ml). Stage distribution was FIGO stage I, 63%; stage II, 6.5%; stage III, 24%; and stage IV, 6.5%. Median follow-up of the study was 19.5 months (range 2–104 months). The estimated median recurrence-free survival of the overall population was 31 months, and the estimated median overall survival of the overall population was 71 months. For stages I and II and stages III and IV who are clubbed together, the estimated median recurrence-free survival was 79 months and 12 months (P = 0.0003 by Mantel–Cox log-rank test) and overall survival was 14 months and 11 months, respectively (P = 0.007).
Majority of our patient population were at an early stage. The mean CA-125 level was higher compared to Western literature. The outcomes of early stage were much better compared to historic outcomes of serous ovarian cancer; however, the outcomes of advanced stage stay dismal. Prospective studies are needed for generating higher quality of evidence.
KeywordsClear cell cancer Ovary cancer East India Epithelial ovarian cancer
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 14.Katsumata N, Yasuda M, Isonishi S, Takahashi F, Michimae H, Kimura E, et al. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol. 2013;14(10):1020–6.CrossRefGoogle Scholar